Skip to main content
Guobang Pharma Ltd. logo

Guobang Pharma Ltd. — Investor Relations & Filings

Ticker · 605507 ISIN · CNE100004NS2 LEI · 300300PS6T4W4PGYPM51 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 510 across all filing types
Latest filing 2026-05-18 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 605507

About Guobang Pharma Ltd.

https://www.gbgcn.com

Guobang Pharma Ltd. specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished dosage forms. The company operates across two primary sectors: human health and animal health. Its product portfolio includes a wide range of anti-infectives, such as macrolides and quinolones, as well as cardiovascular medications and veterinary drugs like florfenicol. Guobang Pharma maintains a comprehensive industrial chain, leveraging large-scale production facilities and advanced chemical synthesis technologies to serve global markets. The organization focuses on providing integrated solutions for pharmaceutical raw materials, emphasizing quality control and regulatory compliance to meet international standards.

Recent filings

Filing Released Lang Actions
国邦医药关于全资子公司参与设立股权投资基金的进展公告
Capital/Financing Update Classification · 85% confidence The document is an SSE-listed company announcement describing its wholly-owned subsidiary’s equity investment in a new fund, detailing capital commitments, changes in partner contributions and percentages, and the impact on the company. This is not a financial report itself nor a simple publication notice; it is a corporate financing/investment activity update. Therefore it fits the 'Capital/Financing Update' category (CAP).
2026-05-18 Chinese
国邦医药2025年年度股东会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance, and voting results of the 2025 Annual General Meeting (AGM) of Guobang Pharmaceutical Group Co., Ltd. It details the legality and validity of the AGM process and the resolutions passed. The document does not contain the actual annual report or financial statements but focuses on the AGM's legal compliance and voting outcomes. This matches the description of 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which covers official results from shareholder votes at general meetings. The document length (7011 characters) and content confirm it is not a brief announcement but a detailed legal opinion on the AGM voting results. Therefore, the correct classification is DVA with high confidence.
2026-04-23 Chinese
国邦医药2026年度“提质增效重回报”行动方案
Regulatory Filings Classification · 90% confidence The document is a detailed announcement from the board of 国邦医药集团股份有限公司 outlining the company's 2026 action plan titled “提质增效重回报”行动方案. It includes strategic goals, business development focus, R&D innovation, governance improvements, investor communication, investor returns, and management responsibilities. The document is not a full annual or interim financial report, nor is it a brief earnings release or a voting result announcement. It is a comprehensive corporate action plan and governance-related communication, but it does not contain actual financial statements or detailed financial data. The length is 3468 characters, which is relatively short and more of a strategic plan announcement rather than a full report. It is not a certification or a regulatory compliance filing. Given the content focuses on company strategy, governance, and investor relations, it best fits under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2026-04-15 Chinese
国邦医药2025年年度股东会会议资料
AGM Information Classification · 100% confidence The document is titled '2025 年年度股东会会议资料' which translates to '2025 Annual General Meeting (AGM) Meeting Materials'. It contains detailed agenda items for the 2025 AGM of Guobang Pharmaceutical Group Co., Ltd., including proposals for the board work report, annual report, profit distribution, auditor appointment, executive remuneration, guarantees for subsidiaries, remuneration management system, and amendments to the company charter. It also includes meeting procedures, voting instructions, and a report from independent directors. The document is clearly the materials prepared and distributed for the AGM meeting itself, not the annual report or other filings. The length is 8017 characters, which is consistent with a detailed AGM information packet. Therefore, the document fits the category of AGM Information (AGM-R).
2026-04-15 Chinese
国邦医药第三届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the third meeting of the third board of directors of Guobang Pharmaceutical Group Co., Ltd. It includes details about the meeting attendance, voting results, and references to other reports (such as the 2026 first quarter report) that are disclosed elsewhere. The document itself does not contain the full quarterly report or detailed financial data but rather announces the board meeting decisions and points to where the full reports can be found. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2026-04-15 Chinese
国邦医药2026年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2026 First Quarter Report" of Guobang Pharmaceutical Group Co., Ltd. It contains detailed financial statements including balance sheet, income statement, and cash flow statement for the first quarter of 2026. The report includes unaudited financial data, key financial metrics, shareholder information, and management assurances about the accuracy of the report. The length of the document (over 10,000 characters) and the presence of comprehensive financial data and analysis confirm it is a substantive financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2026-04-15 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.